Web17 jun. 2024 · Treatment and Follow-Up. The patient was counselled on treatment options; he expressed concern regarding long-term AR exposure; DOCE + ADT was … WebSince 2015, the metastatic hormone sensitive prostate cancer (mHSPC) disease space now has several options of doublet and triplet therapy, using ADT as the backbone of treatment, leading to an overall survival (OS) advantage versus ADT alone. Thus, this has changed the standard of care for treatment intensification for these men.
Patient-reported Outcomes in Metastatic Castration-sensitive Prostate ...
Web23 mei 2024 · ADT plus docetaxel and ADT plus abiraterone are the contemporary standard treatment of mCSPC. ADT plus docetaxel may be considered for patients with mCSPC who have good performance status, have high-volume disease, desire shorter … ing because mCSPC is generally considered to be incurable. Although … The treatment landscape for metastatic castration-sensitive prostate cancer … Wij willen hier een beschrijving geven, maar de site die u nu bekijkt staat dit niet toe. DOI: 10.1200/JCO.2006.06.4246 Journal of Clinical Oncology - published online … Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical … Wij willen hier een beschrijving geven, maar de site die u nu bekijkt staat dit niet toe. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of … Article Types. Submission to the ASCO Educational Book is by invitation only.. … Web16 jun. 2024 · Health Canada Approves XTANDI® (enzalutamide), for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. hopital saint antoine metro
ASCO 2024: Reasons for Oncologist and Urologist Treatment
Web4 apr. 2024 · mCRPC treatment patterns among patients in the US who received treatment with an NHT in mCSPC. mCRPC treatment patterns in the US by mCSPC NHT … Web1 mrt. 2024 · Studies of treatments for mCSPC suggest that the improvements in survival associated with more intensive systemic treatment are accompanied by improvements in QOL. ADT prolongs survival among men with intermediate- or high-risk localized disease in combination with radiation, but the optimal duration is still being defined. WebEvolving landscape of metastatic castration-sensitive prostate cancer (mCSPC) While long-standing use of ADT has been the standard-of-care for metastatic CSPC, this paradigm changed in 2014 when the first of many large, randomized studies investigating the addition of docetaxel chemotherapy to ADT was reported. hopital saint antoine irm